Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer

Oncol Rev. 2023 Sep 20:17:11471. doi: 10.3389/or.2023.11471. eCollection 2023.

John Nemunaitis¹, Laura Stanbery¹, Adam Walter^{1

2}, Rodney Rocconi³, Philip Stephens^{1

4}

¹ Gradalis, Inc, Dallas, TX, United States.
² ProMedica, Toledo, OH, United States.
³ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Mobile, AL, United States.
⁴ Naveris, Waltham, MA, United States.

No abstract available

Keywords: homologous recombination; immune response; immunotherapy; neoantigen; ovarian cancer.